Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors

Blood. 2012 Oct 18;120(16):3382-3. doi: 10.1182/blood-2012-04-424192.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Drug Resistance, Neoplasm / genetics*
  • Follow-Up Studies
  • Fusion Proteins, bcr-abl / genetics*
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality
  • Mutation / genetics*
  • Protein Kinase Inhibitors / therapeutic use*
  • Survival Rate
  • Treatment Outcome

Substances

  • Protein Kinase Inhibitors
  • Fusion Proteins, bcr-abl